The new platform integrates genomic and epigenomic data in a single long-read sequencing assay, providing high-resolution insights into chromatin structure, gene regulation, and disease mechanisms.
Greer Massey, PhD, chief scientific officer at Molecular Designs, shares insights on how labs are affected by the rule’s reversal and how they can prepare for future regulatory changes.
The ARCHER study will evaluate shortened radiation therapy while using ctDNA testing to monitor treatment response and disease recurrence.
CURECA and STAgora technologies aim to eliminate manual intervention in molecular testing workflows and provide actionable diagnostic data insights.
A recent poll highlights growing interest in host response testing for sepsis. Immunexpress CEO Rollie Carlson discusses the findings and the future of rapid diagnostics.
